Petros Pharmaceuticals, Inc.
PTPI
$0.0919
-$0.0106-10.34%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.02M | 4.12M | 4.69M | 5.82M | 6.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.02M | 4.12M | 4.69M | 5.82M | 6.98M |
| Cost of Revenue | 1.11M | 1.23M | 1.41M | 1.63M | 2.35M |
| Gross Profit | 2.92M | 2.89M | 3.28M | 4.19M | 4.63M |
| SG&A Expenses | 10.18M | 9.88M | 9.84M | 9.26M | 9.31M |
| Depreciation & Amortization | 2.98M | 3.07M | 3.17M | 3.28M | 3.40M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.61M | 17.32M | 18.07M | 16.58M | 16.81M |
| Operating Income | -13.59M | -13.20M | -13.38M | -10.76M | -9.82M |
| Income Before Tax | -4.73M | -7.06M | -8.94M | -8.16M | -12.71M |
| Income Tax Expenses | -- | -- | -- | -- | -10.50K |
| Earnings from Continuing Operations | -4.73 | -7.06 | -8.94 | -8.16 | -12.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.73M | -7.06M | -8.94M | -8.16M | -12.70M |
| EBIT | -13.59M | -13.20M | -13.38M | -10.76M | -9.82M |
| EBITDA | -10.61M | -10.13M | -10.21M | -7.48M | -6.43M |
| EPS Basic | -4.69 | -7.01 | -7.84 | -6.82 | -6.75 |
| Normalized Basic EPS | -1.19 | -2.39 | -3.09 | -3.22 | -3.78 |
| EPS Diluted | -4.69 | -7.01 | -7.84 | -6.82 | -6.75 |
| Normalized Diluted EPS | -1.19 | -2.39 | -3.09 | -3.22 | -3.78 |
| Average Basic Shares Outstanding | 24.35M | 16.64M | 11.37M | 8.70M | 8.40M |
| Average Diluted Shares Outstanding | 24.35M | 16.64M | 11.37M | 8.70M | 8.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
